173 related articles for article (PubMed ID: 28114606)
21. Vismodegib as a neoadjuvant treatment to Mohs surgery for aggressive basal cell carcinoma.
Alcalay J; Tauber G; Fenig E; Hodak E
J Drugs Dermatol; 2015 Mar; 14(3):219-23. PubMed ID: 25738842
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of vismodegib in patients with basal cell carcinoma: An Italian Center experience.
Scalvenzi M; Villani A; Costa C; Cappello M
Dermatol Ther; 2019 Jul; 32(4):e12971. PubMed ID: 31124200
[No Abstract] [Full Text] [Related]
23. Hepatotoxicity Associated With Vismodegib: Could Dose Reduction Be an Effective Management?
de Perosanz-Lobo D; Burgos-Blasco P; Moreno-Arrones OM; Bea-Ardebol S
Dermatol Surg; 2021 Jul; 47(7):1006-1007. PubMed ID: 34167133
[No Abstract] [Full Text] [Related]
24. Secondary Resistance to Vismodegib After Initial Successful Treatment of Extensive Recurrent Periocular Basal Cell Carcinoma with Orbital Invasion.
Papastefanou VP; René C
Ophthalmic Plast Reconstr Surg; 2017; 33(3S Suppl 1):S68-S70. PubMed ID: 26398246
[TBL] [Abstract][Full Text] [Related]
25. Histopathology of Basal Cell Carcinoma After Treatment With Vismogedib.
Tang JC; Buckel L; Hanke CW
J Drugs Dermatol; 2019 Feb; 18(2):136-138. PubMed ID: 30794363
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma.
Chang AL; Lewis KD; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
Oncotarget; 2016 Nov; 7(46):76118-76124. PubMed ID: 27764798
[TBL] [Abstract][Full Text] [Related]
27. [Vismodegib Therapy for Periocular Basal Cell Carcinoma].
Keserü M; Green S; Dulz S
Klin Monbl Augenheilkd; 2017 Jan; 234(1):64-69. PubMed ID: 28135752
[No Abstract] [Full Text] [Related]
28. Vismodegib in basal cell carcinoma.
Amaria RN; Bowles DW; Lewis KD; Jimeno A
Drugs Today (Barc); 2012 Jul; 48(7):459-67. PubMed ID: 22844657
[TBL] [Abstract][Full Text] [Related]
29. Two different scenarios of squamous cell carcinoma within advanced Basal cell carcinomas: cases illustrating the importance of serial biopsy during vismodegib usage.
Zhu GA; Sundram U; Chang AL
JAMA Dermatol; 2014 Sep; 150(9):970-3. PubMed ID: 24740281
[TBL] [Abstract][Full Text] [Related]
30. Epidermal cyst formation and hyperkeratosis in a patient treated with vismodegib for locally advanced Basal cell carcinoma.
Reinders MG; Brinkhuizen T; Soetekouw PM; Kelleners-Smeets NW; Hamid MA; Mosterd K
Acta Derm Venereol; 2015 May; 95(5):618-9. PubMed ID: 25425396
[No Abstract] [Full Text] [Related]
31. Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma.
Sagiv O; Nagarajan P; Ferrarotto R; Kandl TJ; Thakar SD; Glisson BS; Altan M; Esmaeli B
Br J Ophthalmol; 2019 Jun; 103(6):775-780. PubMed ID: 30021814
[TBL] [Abstract][Full Text] [Related]
32. Sonic Hedgehog Pathway Blockade After Surgical Debulk of Large Exophytic Basal Cell Carcinomas.
Wirth PJ; Hobbs R; Billingsley E; Vidimos AT; Lam C
Dermatol Surg; 2021 Aug; 47(8):1118-1119. PubMed ID: 34107497
[No Abstract] [Full Text] [Related]
33. PRISModegib: the use of the PRISM test to assess the health-related quality of life of patients with locally advanced basal cell carcinoma undergoing Hedgehog pathway inhibitor therapy.
Gualdi G; Moro R; Regina V; Caravello S; Monari P; Calzavara-Pinton PG
Br J Dermatol; 2019 Aug; 181(2):406-407. PubMed ID: 30737996
[No Abstract] [Full Text] [Related]
34. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
35. Neglected skin carcinomas and Vismodegib: our experience.
Russo F; Mancini V; Taddeucci P; Cirocco A; Cusano F; Pellegrino M; Sirna R
G Ital Dermatol Venereol; 2019 Oct; 154(5):597-599. PubMed ID: 29417798
[No Abstract] [Full Text] [Related]
36. [Successful therapy of metastatic basal cell carcinoma with vismodegib].
Zutt M; Mazur F; Bergmann M; Lemke AJ; Kaune KM
Hautarzt; 2014 Nov; 65(11):974-7. PubMed ID: 25217085
[TBL] [Abstract][Full Text] [Related]
37. Vismodegib and the Hedgehog Pathway Inhibitors: A Historical Perspective to Current Clinical Application.
Tang JC; Hanke CW; Caro I
J Drugs Dermatol; 2018 May; 17(5):506-508. PubMed ID: 29742180
[TBL] [Abstract][Full Text] [Related]
38. Vismodegib, itraconazole and sonidegib as hedgehog pathway inhibitors and their relative competencies in the treatment of basal cell carcinomas.
Wahid M; Jawed A; Mandal RK; Dar SA; Khan S; Akhter N; Haque S
Crit Rev Oncol Hematol; 2016 Feb; 98():235-41. PubMed ID: 26614022
[TBL] [Abstract][Full Text] [Related]
39. Fast growing melanoma following treatment with vismodegib for locally advanced basal cell carcinomas: report of two cases.
Giuffrida R; Kashofer K; Dika E; Patrizi A; Baraldi C; Di Meo N; Zalaudek I
Eur J Cancer; 2018 Mar; 91():177-179. PubMed ID: 29373258
[No Abstract] [Full Text] [Related]
40. New perspectives in the management of basal cell carcinoma.
Martín-Gorgojo A; Pastushenko I
Actas Dermosifiliogr; 2014 Nov; 105(9):874-5. PubMed ID: 24934656
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]